Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer aims to spot hidden cancers

NCT ID NCT07602569

Diagnosis Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new radioactive tracer called 18F-FGln, which targets glutamine—a nutrient that cancer cells need to grow. Researchers want to see if PET/CT scans using this tracer can more accurately detect and stage various cancers, especially those that are hard to see with standard scans. The study will involve 110 people with suspected or confirmed cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FGln (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could provide a more accurate way to diagnose and stage certain cancers, especially where current scans may miss or misread tumors.
What could go wrong
This is an early-stage study with only 110 participants, so results may not apply to all cancers. The tracer's effectiveness compared to standard methods is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include patients from the Affiliated Cancer Hospital \& Institute of Guangzhou Medical University who underwent an 18F-FGln PET/CT scan between October 2025 and January 2028 . Eligible participants are adult patients aged 18 to 70 years with suspected or histopathologically confirmed malignant tumors. Patients with non-malignant lesions, pregnant women, and those with incomplete medical records or missing histopathological reference standards will be excluded. Data will be collected by reviewing the institutional medical records and PET/CT imaging database.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives) 2. Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy 3. Patients without other tumor history 4. Patients with good compliance, providing informed consent, and able to follow the research protocol Exclusion Criteria: 1. pregnant or lactating patients or patients under 18 years old 2. the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent; 3. patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations. 4. those who have undergone gastrointestinal barium meal examination within one week; 5. other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer (with or without metastasis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer (with or without metastasis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    RECRUITING

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.